Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ASO Author Reflections: TP53 and PKD Co-mutations Were Associated with Poorer Prognoses in Patients with Resected EGFR-Mutated Lung Adenocarcinoma.

Annals of surgical oncology - 1 Dec 2019

Long Hao, Liu Di-Han

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Antineoplastic Combined Chemotherapy Protocols
Share to Biomarkers, Tumor
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Protein Kinase C

Share to Survival Rate

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 31741107
DOI: 10.1245/s10434-019-08079-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ASO Author Reflections: TP53 and PKD Co-mutations Were Associated with Poorer Prognoses in Patients with Resected EGFR-Mutated Lung Adenocarcinoma.PMID 31741107Read ↗

TP53 co-mutations in advanced lung adenocarcinoma: comparative bioinformatic analyses suggest ambivalent character on overall survival alongside KRAS, STK11 and KEAP1 mutationsSemantic proximity Read ↗

ASO Author Reflections: Constructed Scoring System Using TP53 and SMAD4 Mutations Combined with Carbohydrate Antigen 19-9 in Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

The clinical features and prognostic implications of the co-mutated TP53 gene in advanced non-small cell lung cancer.Semantic proximity Read ↗

ASO Author Reflections: From Susceptibility Loci to Oncologically Relevant SNPs in Upper Gastrointestinal Cancer.Semantic proximity Read ↗

TP53 Co-Mutations in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer TherapySemantic proximity Read ↗

Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors.Semantic proximity Read ↗

TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLCSemantic proximity Read ↗

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

Different co-mutations in triple EGFR mutated adenocarcinomas in a patient.Semantic proximity Read ↗

Combined Effect of Genetic Polymorphisms in P53, P73, and MDM2 on Non-small Cell Lung Cancer SurvivalSemantic proximity Read ↗

Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.Semantic proximity Read ↗

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.